Ind-Swift Ltd Competitors & Peer Comparison
Pharmaceuticals · Indian listed companies
Compare Ind-Swift Ltd with 125 companies shown from the same industry classification, including Denis Chem Lab Ltd, Fervent Synergies Ltd, Concord Drugs Ltd. These are industry peers; their products, customers and business models may differ.
Selected-company price and ratio data: . Peer reporting dates can differ. Stored figures, not live quotes.
Compare valuation, size and returns
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Ind-Swift Ltd | 85.4 Cr. | 15.8 | / | 10.9 | 74.2 | 0.00 % | 11.9 % | % | 2.00 |
| Denis Chem Lab Ltd | 93.3 Cr. | 67.3 | 97.4/56.1 | 11.7 | 66.0 | 3.72 % | 14.0 % | 9.52 % | 10.0 |
| Fervent Synergies Ltd | 73.3 Cr. | 14.7 | 26.0/13.0 | 20.1 | 11.4 | 0.00 % | 7.21 % | 7.22 % | 10.0 |
| Concord Drugs Ltd | 101 Cr. | 76.9 | 92.5/61.0 | 49.7 | 36.8 | 0.00 % | 5.19 % | 2.52 % | 10.0 |
| Pharmaids Pharmaceuticals Ltd | 106 Cr. | 30.2 | 60.0/25.6 | 13.5 | 0.00 % | 18.5 % | 26.5 % | 10.0 | |
| Vaishali Pharma Ltd | 108 Cr. | 8.28 | 11.9/4.75 | 25.5 | 5.29 | 0.00 % | 8.93 % | 6.02 % | 2.00 |
| Cian Healthcare Ltd | 62.4 Cr. | 25.0 | 25.0/4.72 | 3.42 | 0.00 % | 15.1 % | 49.2 % | 10.0 | |
| ANG Lifesciences India Ltd | 51.4 Cr. | 39.4 | 49.7/17.6 | 47.6 | 0.00 % | 1.14 % | 7.38 % | 10.0 | |
| Vivimed Labs Ltd | 50.6 Cr. | 5.99 | 29.4/4.75 | 25.4 | 0.00 % | 65.2 % | % | 2.00 | |
| Alpa Laboratories Ltd | 123 Cr. | 59.0 | 99.8/46.0 | 28.1 | 93.4 | 0.00 % | 8.91 % | 7.90 % | 10.0 |
| Biofil Chemicals & Pharmaceuticals Ltd | 47.7 Cr. | 29.6 | 46.8/25.6 | 99.4 | 13.2 | 0.00 % | 2.97 % | 2.83 % | 10.0 |
| Mangalam Drugs and Organics Ltd | 46.4 Cr. | 29.2 | 74.0/22.7 | 65.3 | 0.00 % | 14.0 % | 34.8 % | 10.0 | |
| Godavari Drugs Ltd | 127 Cr. | 116 | 135/69.7 | 32.6 | 74.8 | 0.00 % | 6.55 % | 6.14 % | 10.0 |
| Bacil Pharma Ltd | 39.1 Cr. | 27.3 | 61.8/10.6 | 60.2 | 17.3 | 0.00 % | 3.93 % | 6.21 % | 10.0 |
| Murae Organisor Ltd | 38.8 Cr. | 0.19 | 0.53/0.19 | 2.56 | 1.02 | 0.00 % | 4.20 % | 5.69 % | 1.00 |
| Gujarat Inject (Kerala) Ltd | 134 Cr. | 9.14 | 14.3/1.96 | 44.6 | 0.81 | 0.00 % | 22.9 % | 16.6 % | 1.00 |
| Lactose (India) Ltd | 135 Cr. | 107 | 136/76.0 | 19.4 | 51.5 | 0.00 % | 11.3 % | 9.81 % | 10.0 |
| Krebs Biochemicals & Industries Ltd | 135 Cr. | 64.0 | 76.8/38.3 | 75.5 | 0.00 % | 15.4 % | % | 10.0 | |
| Chandra Bhagat Pharma Ltd | 35.4 Cr. | 46.9 | 53.0/29.7 | 11.6 | 43.9 | 0.00 % | 12.1 % | 9.67 % | 10.0 |
| Bharat Immunological & Biological Corporation Ltd | 32.5 Cr. | 7.53 | 22.6/7.42 | 18.2 | 0.00 % | 9.27 % | 17.7 % | 10.0 | |
| Achyut Healthcare Ltd | 139 Cr. | 5.74 | 10.0/4.70 | 433 | 1.45 | 0.00 % | 1.18 % | 0.96 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 26.9 Cr. | 34.5 | 59.8/29.0 | 12.1 | 12.5 | 0.00 % | 39.2 % | 30.2 % | 10.0 |
| Auro Laboratories Ltd | 144 Cr. | 231 | 317/159 | 30.0 | 74.4 | 0.00 % | 9.52 % | 8.49 % | 10.0 |
| Colinz Laboratories Ltd | 18.4 Cr. | 73.0 | 87.9/36.1 | 36.8 | 39.9 | 0.00 % | 7.20 % | 5.23 % | 10.0 |
| Checkpoint Trends Ltd | 18.0 Cr. | 32.8 | 144/28.4 | 14.6 | 42.5 | 0.00 % | 15.0 % | 12.7 % | 10.0 |
| Ortin Laboratories Ltd | 16.4 Cr. | 20.1 | 26.4/16.2 | 3.47 | 0.00 % | 60.2 % | 118 % | 10.0 | |
| Par Drugs & Chemicals Ltd | 155 Cr. | 126 | 180/78.0 | 10.7 | 91.0 | 0.00 % | 14.6 % | 9.95 % | 10.0 |
| Desh Rakshak Aushdhalaya Ltd | 15.3 Cr. | 26.9 | 59.6/22.4 | 27.9 | 23.3 | 0.00 % | 7.50 % | 5.59 % | 10.0 |
| Beryl Drugs Ltd | 12.6 Cr. | 24.8 | 27.6/15.9 | 20.3 | 19.5 | 0.00 % | 7.25 % | 4.34 % | 10.0 |
| Brooks Laboratories Ltd | 159 Cr. | 54.2 | 138/36.3 | 12.0 | 41.6 | 0.00 % | 21.2 % | 22.0 % | 10.0 |
| Chemo Pharma Laboratories Ltd | 11.4 Cr. | 75.9 | 153/70.0 | 8.60 | 0.00 % | 0.28 % | 0.28 % | 10.0 | |
| Dipna Pharmachem Ltd | 11.2 Cr. | 4.28 | 25.0/3.90 | 4.28 | 23.7 | 0.00 % | 7.64 % | 5.22 % | 10.0 |
| Adline Chem Lab Ltd | 9.24 Cr. | 15.8 | 17.1/7.60 | 3.03 | 0.00 % | 1,267 % | % | 10.0 | |
| Ganga Pharmaceuticals Ltd | 7.39 Cr. | 12.5 | 14.0/9.35 | 73.9 | 14.1 | 0.00 % | 2.90 % | 1.30 % | 10.0 |
| Brawn Biotech Ltd | 7.35 Cr. | 24.5 | 24.7/17.7 | 8.65 | 14.5 | 0.00 % | 0.00 % | 24.4 % | 10.0 |
| Decipher Labs Ltd | 5.73 Cr. | 5.67 | 11.0/5.00 | 20.5 | 0.00 % | 16.7 % | 14.2 % | 10.0 | |
| Amerise Biosciences Ltd | 5.22 Cr. | 0.79 | 1.03/0.50 | 0.82 | 0.00 % | 0.37 % | 0.37 % | 1.00 | |
| Fabino Enterprises Ltd | 4.27 Cr. | 20.3 | 27.0/13.0 | 18.7 | 0.00 % | 6.22 % | 8.76 % | 10.0 | |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 2.08/1.57 | 0.04 | 0.00 % | 13.1 % | 177 % | 10.0 | |
| Evoq Remedies Ltd | 3.78 Cr. | 1.52 | 6.11/1.35 | 17.8 | 0.00 % | 0.56 % | 0.54 % | 10.0 | |
| Bal Pharma Ltd | 170 Cr. | 107 | 125/59.7 | 23.6 | 51.6 | 1.12 % | 9.69 % | 7.87 % | 10.0 |
| Coral Laboratories Ltd | 201 Cr. | 562 | 679/360 | 10.6 | 585 | 0.36 % | 11.0 % | 7.79 % | 10.0 |
| Nectar Lifescience Ltd | 202 Cr. | 10.5 | 22.5/9.20 | 30.0 | 0.00 % | 0.05 % | 31.3 % | 1.00 | |
| Ambalal Sarabhai Enterprises Ltd | 203 Cr. | 26.5 | 42.0/23.1 | 11.4 | 19.2 | 0.00 % | 9.12 % | 6.25 % | 10.0 |
| Everest Organics Ltd | 235 Cr. | 236 | 536/197 | 44.8 | 77.7 | 0.00 % | 12.0 % | 7.63 % | 10.0 |
| Gennex Laboratories Ltd | 241 Cr. | 9.93 | 17.2/7.05 | 12.8 | 9.16 | 0.00 % | 11.8 % | 10.5 % | 1.00 |
| BDH Industries Ltd | 273 Cr. | 474 | 610/340 | 23.3 | 134 | 1.06 % | 20.5 % | 14.8 % | 10.0 |
| Lyka Labs Ltd | 277 Cr. | 77.5 | 105/44.1 | 25.9 | 0.00 % | 5.98 % | 10.2 % | 10.0 | |
| Aarey Drugs & Pharmaceuticals Ltd | 334 Cr. | 104 | 108/50.3 | 80.2 | 53.0 | 0.00 % | 5.58 % | 2.75 % | 10.0 |
| SMS Lifesciences India Ltd | 357 Cr. | 1,197 | 1,680/956 | 20.6 | 650 | 0.13 % | 11.8 % | 10.8 % | 10.0 |
| Albert David Ltd | 481 Cr. | 836 | 932/580 | 21.3 | 686 | 0.60 % | 0.82 % | 0.44 % | 10.0 |
| Wanbury Ltd | 663 Cr. | 190 | 360/162 | 15.4 | 18.1 | 0.00 % | 36.6 % | 76.5 % | 10.0 |
| Kilitch Drugs (India) Ltd | 826 Cr. | 234 | 248/117 | 27.5 | 80.0 | 0.00 % | 13.4 % | 10.6 % | 10.0 |
| Anuh Pharma Ltd | 833 Cr. | 84.2 | 99.5/66.7 | 18.9 | 35.1 | 1.78 % | 14.9 % | 10.7 % | 5.00 |
| Bafna Pharmaceuticals Ltd | 899 Cr. | 386 | 393/94.8 | 115 | 40.6 | 0.00 % | 11.9 % | 12.3 % | 10.0 |
| Themis Medicare Ltd | 1,031 Cr. | 113 | 147/65.0 | 43.3 | 0.44 % | 2.74 % | 0.41 % | 1.00 | |
| Lincoln Pharmaceuticals Ltd | 1,136 Cr. | 567 | 770/440 | 11.8 | 378 | 0.32 % | 16.3 % | 12.3 % | 10.0 |
| Kopran Ltd | 1,298 Cr. | 269 | 296/107 | 51.9 | 110 | 1.12 % | 6.65 % | 4.91 % | 10.0 |
| TTK Healthcare Ltd | 1,422 Cr. | 1,007 | 1,250/735 | 18.6 | 789 | 0.99 % | 8.04 % | 6.30 % | 10.0 |
| Amrutanjan Health Care Ltd | 1,496 Cr. | 518 | 760/476 | 24.0 | 128 | 0.95 % | 24.8 % | 18.4 % | 1.00 |
| Jagsonpal Pharmaceuticals Ltd | 1,515 Cr. | 229 | 265/155 | 32.2 | 41.2 | 1.74 % | 22.7 % | 17.3 % | 2.00 |
| Fermenta Biotech Ltd | 1,628 Cr. | 553 | 580/249 | 29.8 | 138 | 0.68 % | 20.6 % | 16.4 % | 5.00 |
| Hester Biosciences Ltd | 1,780 Cr. | 2,106 | 2,684/1,239 | 33.5 | 423 | 0.52 % | 15.2 % | 15.9 % | 10.0 |
| Panacea Biotec Ltd | 2,152 Cr. | 350 | 648/292 | 136 | 0.00 % | 2.43 % | 2.42 % | 1.00 | |
| Syncom Formulations (India) Ltd | 2,174 Cr. | 23.1 | 27.5/10.2 | 25.6 | 4.39 | 0.43 % | 24.8 % | 17.6 % | 1.00 |
| Beta Drugs Ltd | 2,222 Cr. | 2,004 | 2,808/990 | 48.7 | 241 | 0.00 % | 19.2 % | 18.8 % | 10.0 |
| Fredun Pharmaceuticals Ltd | 2,241 Cr. | 1,355 | 1,600/454 | 50.4 | 170 | 0.02 % | 21.5 % | 15.8 % | 10.0 |
| Indoco Remedies Ltd | 2,278 Cr. | 247 | 317/162 | 102 | 0.08 % | 0.96 % | 9.36 % | 2.00 | |
| Dishman Carbogen Amcis Ltd | 2,369 Cr. | 152 | 307/128 | 131 | 426 | 0.00 % | 3.14 % | 1.58 % | 2.00 |
| Venus Remedies Ltd | 2,393 Cr. | 1,778 | 2,044/432 | 20.6 | 497 | 0.56 % | 20.7 % | 15.6 % | 10.0 |
| Hikal Ltd | 2,644 Cr. | 214 | 261/146 | 62.4 | 97.2 | 0.28 % | 3.50 % | 2.21 % | 2.00 |
| Advanced Enzyme Technologies Ltd | 3,049 Cr. | 272 | 420/252 | 19.3 | 146 | 1.96 % | 14.0 % | 10.2 % | 2.00 |
| Solara Active Pharma Sciences Ltd | 3,280 Cr. | 677 | 774/422 | 768 | 346 | 0.00 % | 4.86 % | 0.13 % | 10.0 |
| Ind-Swift Laboratories Ltd | 3,354 Cr. | 386 | 425/87.0 | 51.5 | 159 | 0.00 % | 4.86 % | 4.02 % | 10.0 |
| Unichem Laboratories Ltd | 3,739 Cr. | 531 | 687/278 | 30.6 | 386 | 0.00 % | 4.13 % | 3.17 % | 2.00 |
| Kwality Pharmaceuticals Ltd | 3,773 Cr. | 3,644 | 3,949/829 | 46.2 | 321 | 0.00 % | 23.9 % | 22.5 % | 10.0 |
| Aarti Drugs Limited | 3,778 Cr. | 415 | 534/319 | 21.8 | 154 | 0.48 % | 11.7 % | 12.7 % | 10.0 |
| Gufic BioSciences Ltd | 4,211 Cr. | 420 | 468/268 | 57.3 | 66.2 | 0.02 % | 12.2 % | 9.98 % | 1.00 |
| SMS Pharmaceuticals Ltd | 4,472 Cr. | 478 | 494/262 | 49.4 | 85.9 | 0.08 % | 12.9 % | 11.9 % | 1.00 |
| Zota Health Care Ltd | 4,493 Cr. | 1,297 | 1,740/1,022 | 200 | 0.08 % | 8.47 % | 15.0 % | 10.0 | |
| RPG Life Sciences Ltd | 4,780 Cr. | 2,896 | 3,130/1,731 | 41.0 | 366 | 0.83 % | 25.7 % | 19.3 % | 8.00 |
| Gujarat Themis Biosyn Ltd | 4,842 Cr. | 372 | 479/225 | 99.4 | 26.4 | 0.17 % | 18.1 % | 17.4 % | 1.00 |
| FDC Ltd | 5,400 Cr. | 331 | 476/313 | 17.5 | 153 | 1.51 % | 15.4 % | 11.2 % | 1.00 |
| Orchid Pharma Ltd | 5,775 Cr. | 966 | 1,144/471 | 320 | 300 | 0.00 % | 1.86 % | 1.49 % | 10.0 |
| IOL Chemicals & Pharmaceuticals Ltd | 6,036 Cr. | 206 | 219/67.1 | 34.2 | 61.3 | 0.49 % | 11.3 % | 8.42 % | 2.00 |
| Sanofi India Ltd | 6,978 Cr. | 3,024 | 4,898/3,000 | 20.4 | 359 | 2.48 % | 57.5 % | 43.0 % | 10.0 |
| Bliss GVS Pharma Ltd | 7,063 Cr. | 665 | 745/118 | 51.3 | 113 | 0.23 % | 16.9 % | 11.8 % | 1.00 |
| Entero Healthcare Solutions Ltd | 7,378 Cr. | 1,697 | 1,920/944 | 57.2 | 388 | 0.00 % | 10.5 % | 6.94 % | 10.0 |
| Morepen Laboratories Ltd | 7,414 Cr. | 135 | 138/33.0 | 63.2 | 22.8 | 0.15 % | 8.05 % | 5.33 % | 2.00 |
| Aarti Pharmalabs Ltd | 8,603 Cr. | 947 | 1,002/584 | 40.0 | 234 | 0.37 % | 10.7 % | 8.59 % | 5.00 |
| Suven Life Sciences Ltd | 8,649 Cr. | 306 | 403/124 | 22.4 | 0.00 % | 79.5 % | 81.5 % | 1.00 | |
| Sequent Scientific Ltd | 8,768 Cr. | 201 | 260/111 | 203 | 32.2 | 0.00 % | 8.47 % | 3.21 % | 2.00 |
| Procter & Gamble Health Ltd | 8,791 Cr. | 5,300 | 6,975/4,700 | 26.4 | 316 | 2.92 % | 83.9 % | 61.9 % | 10.0 |
| Blue Jet Healthcare Ltd | 10,055 Cr. | 532 | 693/325 | 42.8 | 78.4 | 0.23 % | 26.1 % | 19.4 % | 2.00 |
| Concord Biotech Ltd | 14,175 Cr. | 1,356 | 1,648/987 | 49.8 | 193 | 0.56 % | 17.4 % | 12.6 % | 1.00 |
| Astrazeneca Pharma India Ltd | 14,774 Cr. | 5,909 | 9,850/5,882 | 85.2 | 349 | 0.61 % | 29.3 % | 23.3 % | 2.00 |
| Marksans Pharma Ltd | 15,048 Cr. | 332 | 351/155 | 29.1 | 66.7 | 0.27 % | 18.8 % | 15.2 % | 1.00 |
| Jubilant Pharmova Ltd | 15,616 Cr. | 982 | 1,185/784 | 40.2 | 445 | 0.51 % | 8.99 % | 6.53 % | 1.00 |
| Natco Pharma Ltd | 16,106 Cr. | 822 | 1,217/786 | 14.1 | 470 | 0.61 % | 17.4 % | 17.1 % | 2.00 |
| Alembic Pharmaceuticals Ltd | 16,344 Cr. | 831 | 998/635 | 21.9 | 289 | 1.44 % | 12.6 % | 13.4 % | 2.00 |
| ERIS Lifesciences Ltd | 16,490 Cr. | 1,189 | 1,740/1,163 | 25.2 | 282 | 0.61 % | 14.1 % | 18.7 % | 1.00 |
| Cohance Lifesciences Ltd | 17,089 Cr. | 447 | 918/267 | 159 | 102 | 0.00 % | 5.81 % | 4.89 % | 1.00 |
| Pfizer Ltd | 17,595 Cr. | 3,842 | 5,578/3,792 | 22.9 | 919 | 1.95 % | 24.1 % | 18.0 % | 10.0 |
| Caplin Point Laboratories Ltd | 19,790 Cr. | 2,604 | 2,991/1,500 | 29.7 | 443 | 0.31 % | 24.2 % | 20.9 % | 2.00 |
| Shilpa Medicare Ltd | 20,177 Cr. | 1,031 | 1,096/260 | 71.0 | 132 | 0.06 % | 10.9 % | 8.99 % | 1.00 |
| Granules India Ltd | 22,319 Cr. | 817 | 924/520 | 34.3 | 205 | 0.21 % | 15.5 % | 13.8 % | 1.00 |
| Acutaas Chemicals Ltd | 25,572 Cr. | 3,122 | 3,740/1,374 | 66.2 | 202 | 0.08 % | 31.6 % | 24.0 % | 5.00 |
| Neuland Laboratories Ltd | 28,077 Cr. | 21,875 | 24,235/11,500 | 56.4 | 1,461 | 0.16 % | 26.5 % | 21.2 % | 10.0 |
| Wockhardt Ltd | 33,488 Cr. | 2,064 | 2,422/1,087 | 84.0 | 304 | 0.00 % | 7.55 % | 6.11 % | 5.00 |
| J B Chemicals & Pharmaceuticals Ltd | 38,677 Cr. | 2,409 | 2,526/1,603 | 53.8 | 259 | 0.91 % | 25.4 % | 18.9 % | 1.00 |
| Ajanta Pharma Ltd | 43,546 Cr. | 3,486 | 3,797/2,380 | 38.4 | 362 | 0.92 % | 34.5 % | 27.1 % | 2.00 |
| Glaxosmithkline Pharmaceuticals Ltd | 46,239 Cr. | 2,733 | 3,121/2,088 | 43.9 | 134 | 2.09 % | 61.4 % | 45.6 % | 10.0 |
| Gland Pharma Ltd | 48,056 Cr. | 2,912 | 3,042/1,574 | 34.0 | 656 | 0.69 % | 17.4 % | 12.8 % | 1.00 |
| Ipca Laboratories Ltd | 49,578 Cr. | 1,951 | 2,039/1,252 | 36.1 | 318 | 0.31 % | 17.0 % | 15.7 % | 1.00 |
| Abbott India Ltd | 55,776 Cr. | 26,240 | 30,655/25,135 | 34.5 | 2,247 | 2.00 % | 44.8 % | 34.4 % | 10.0 |
| Biocon Ltd | 60,234 Cr. | 370 | 447/338 | 82.8 | 210 | 0.14 % | 3.61 % | 1.40 % | 5.00 |
| Alkem Laboratories Ltd | 61,847 Cr. | 5,192 | 5,934/5,051 | 27.2 | 1,156 | 1.02 % | 21.2 % | 18.9 % | 2.00 |
| Glenmark Life Sciences Ltd | 64,392 Cr. | 2,282 | 2,538/1,793 | 20.6 | 372 | 0.21 % | 39.8 % | 23.6 % | 1.00 |
| Glenmark Pharmaceuticals Ltd | 64,624 Cr. | 2,295 | 2,538/1,793 | 20.7 | 372 | 0.22 % | 39.8 % | 23.6 % | 1.00 |
| Lupin Ltd | 92,061 Cr. | 2,011 | 2,530/1,900 | 15.5 | 491 | 0.90 % | 29.9 % | 28.7 % | 2.00 |
| Aurobindo Pharma Ltd | 96,474 Cr. | 1,675 | 1,740/1,066 | 25.5 | 652 | 0.24 % | 12.9 % | 10.1 % | 1.00 |
| Dr Reddys Laboratories Ltd | 1,00,922 Cr. | 1,203 | 1,415/1,080 | 31.3 | 454 | 0.67 % | 13.0 % | 11.2 % | 1.00 |
| Mankind Pharma Ltd | 1,02,718 Cr. | 2,479 | 2,642/1,910 | 45.4 | 397 | 0.04 % | 13.7 % | 13.8 % | 1.00 |
| Laurus Labs Ltd | 1,06,249 Cr. | 1,971 | 2,055/843 | 122 | 97.3 | 0.10 % | 16.0 % | 15.2 % | 2.00 |
| Cipla Ltd | 1,07,663 Cr. | 1,336 | 1,673/1,166 | 30.1 | 426 | 0.97 % | 15.5 % | 11.6 % | 2.00 |
| Torrent Pharmaceuticals Ltd | 1,81,715 Cr. | 4,772 | 5,250/3,480 | 81.4 | 248 | 0.80 % | 15.2 % | 27.4 % | 5.00 |
| Industry Average | 17,412.37 Cr | 1,241.02 | 54.22 | 211.24 | 0.39% | 26.16% | 16.59% | 6.06 |
How to use this peer comparison
Start with similar company sizes, then compare P/E with ROCE and ROE. A lower P/E alone does not establish better value. Negative earnings, unusual items, debt and different reporting dates can make ratios unsuitable for direct comparison.
The company list is ordered by market-cap proximity to Ind-Swift Ltd, with P/E as a secondary comparison. The industry-average row uses available stored values across the industry, which can include companies beyond the rows shown. Missing values are not zero.
Open each company report for financial statements and its cited sources. Industry classifications indicate a research peer group, not a verified list of direct commercial competitors.
Read the full Ind-Swift Ltd analysis · Explore all Pharmaceuticals stocks